It activates one receptor
SPL UNCLASSIFIED SECTION Gastrointestinal Adverse Reactions In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5 mg 56%, 10 mg 56%, 15 mg 56%) than placebo (30%)
Combined with optional Precision Peptide Genetic Testing ($298), PlexusDx creates a tailored, affordable pathway to sustainable weight loss even after gallbladder removal
The mechanism of action of Mounjaro (Tirzepatide) involves its active ingredient, Tirzepatide, which can simultaneously act on both GIP and GLP-1 intestinal hormone receptors, resulting in multiple metabolic benefits: This medication, by activating both the GIP and GLP-1 receptors, not only stimulates insulin secretion but also helps regulate appetite, reduce food intake, and enhance satiety, providing a comprehensive approach to weight control

Pre-existing risk factors for gallstone disease include: Female sex : Women are two to three times more likely to develop gallstones than men, particularly during reproductive years due to hormonal influences Age over 40 years : Gallstone prevalence increases progressively with age Obesity : Higher body mass index correlates with increased gallstone risk, creating a paradox where the condition being treated is itself a risk factor Rapid weight loss history : Previous episodes of quick weight reduction may indicate susceptibility Pregnancy or recent pregnancy : Hormonal changes affect bile composition and gallbladder motility Family history : Genetic factors contribute to gallstone formation Certain ethnicities : Native American and Hispanic populations have higher gallstone prevalence Metabolic syndrome and diabetes : These conditions are associated with altered bile metabolism The rate and magnitude of weight loss during semaglutide treatment significantly influence gallbladder complication risk

Special situations and considerations Injecting during weight loss As you lose weight on retatrutide, your body composition changes